Ensysce Biosciences (ENSCW) Non-Current Assets (2017 - 2025)
Ensysce Biosciences (ENSCW) reported Non-Current Assets of $207461.0 for Q4 2025, down 17.85% year-over-year from $252550.0 in Q4 2024, and down 17.41% quarter-over-quarter from $251194.0 in Q3 2025.
Ensysce Biosciences (ENSCW) Non-Current Assets (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 9 years of Non-Current Assets data on file, last reported at $207461.0 in Q4 2025.
- Non-Current Assets for Q4 2025 came in at $207461.0, down 17.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $962398.0 (down 23.63% YoY), and the FY2025 annual result was $207461.0, down 17.85% from the prior year.
- Non-Current Assets fell to $207461.0 in Q4 2025 per ENSCW's latest filing, from $251194.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $12.8 million in Q1 2021 and troughed at $207461.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $481716.5 in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2022: Non-Current Assets soared 19100.1% in 2021, then tumbled 94.41% in 2022.
- A 5-year view of Non-Current Assets shows it stood at $754756.0 in 2021, then decreased by 22.37% to $585883.0 in 2022, then declined by 28.45% to $419217.0 in 2023, then plunged by 39.76% to $252550.0 in 2024, then dropped by 17.85% to $207461.0 in 2025.
- Business Quant data shows ENSCW's Non-Current Assets at $207461.0 in Q4 2025, $251194.0 in Q3 2025, and $292860.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Ensysce Biosciences | - | - | - | 207,461.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 207,461.00 |
| Sep 30, 2025 | 251,194.00 |
| Jun 30, 2025 | 292,860.00 |
| Mar 31, 2025 | 210,883.00 |
| Dec 31, 2024 | 252,550.00 |
| Sep 30, 2024 | 294,217.00 |
| Jun 30, 2024 | 335,883.00 |
| Mar 31, 2024 | 377,550.00 |
| Dec 31, 2023 | 419,217.00 |
| Sep 30, 2023 | 460,883.00 |
| Jun 30, 2023 | 502,550.00 |
| Mar 31, 2023 | 544,217.00 |
| Dec 31, 2022 | 585,883.00 |
| Sep 30, 2022 | 627,550.00 |
| Jun 30, 2022 | 754,242.00 |
| Mar 31, 2022 | 713,090.00 |
| Dec 31, 2021 | 754,756.00 |
| Sep 30, 2021 | 796,423.00 |
| Jun 30, 2021 | 838,141.00 |
| Mar 31, 2021 | 12.75 Mn |